Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 May 14

PMID 35565348

Authors

David Schweer

Annabel McAtee

Khaga Neupane

Christopher Richards

Frederick Ueland

Jill Kolesar

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment (TME) has been implicated to play an important role in the progression of ovarian cancer. One of the most important components of the TME is tumor associated macrophages (TAMs). Phenotypically, macrophages are broadly categorized as M1 pro-inflammatory or M2 anti-inflammatory, based on the cytokines and chemokines that they secrete. The tumor microenvironment is associated with macrophages of an M2 phenotype which suppress the surrounding immune environment, assist tumor cells in evading immune targeting, and support tumor growth and metastasis. Contrarily, M1 macrophages help mount an immune response against tumors, and are associated with a more favorable prognosis in solid tumors. One of the characteristic indicators of a poor prognosis in ovarian cancer is the overrepresentation of M2-type TAMs. As such, therapeutic modalities targeting TME and TAMs are of increasing interest. Pharmacological approaches to eliminate TAMs, include decreasing macrophage survival and recruitment and increasing phagocytosis, have been underwhelming. Clinical strategies targeting these macrophage subtypes via repolarization to an M1 antitumoral state deserve increasing attention, and may serve as a new modality for immunotherapy.

Citing Articles

Macrophage-derived lncRNAs in cancer: regulators of tumor progression and therapeutic targets.

Suliman M, Saleh R, Chandra M, Rasool K, Jabir M, Jawad S Med Oncol. 2025; 42(4):91.

PMID: 40048034 DOI: 10.1007/s12032-025-02643-2.

Enhanced Expression of TRIM46 in Ovarian Cancer Cells Induced by Tumor-Associated Macrophages Promotes Invasion via the Wnt/β-Catenin Pathway.

Wang Y, Choi M, Kim J, Choi J Cells. 2025; 14(3).

PMID: 39937005 PMC: 11817100. DOI: 10.3390/cells14030214.

Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities.

Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B J Inflamm Res. 2025; 18:895-909.

PMID: 39867950 PMC: 11762012. DOI: 10.2147/JIR.S503479.

Col1A1 as a new decoder of clinical features and immune microenvironment in ovarian cancer.

Xiao X, Long F, Yu S, Wu W, Nie D, Ren X Front Immunol. 2025; 15():1496090.

PMID: 39845977 PMC: 11750837. DOI: 10.3389/fimmu.2024.1496090.

Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study.

Ye L, Long C, Xu B, Yao X, Yu J, Luo Y Mol Med. 2025; 31(1):5.

PMID: 39773329 PMC: 11707953. DOI: 10.1186/s10020-024-01036-x.

References

Cai L, Zhang G, Tong X, You Q, An Y, Wang Y . Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. Eur J Obstet Gynecol Reprod Biol. 2009; 148(1):73-80. DOI: 10.1016/j.ejogrb.2009.09.018. View

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

Zhang Q, Li H, Mao Y, Wang X, Zhang X, Yu X . Apoptotic SKOV3 cells stimulate M0 macrophages to differentiate into M2 macrophages and promote the proliferation and migration of ovarian cancer cells by activating the ERK signaling pathway. Int J Mol Med. 2019; 45(1):10-22. PMC: 6889918. DOI: 10.3892/ijmm.2019.4408. View

Rodriguez G, Haisley C, Hurteau J, Moser T, Whitaker R, Bast Jr R . Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol. 2001; 80(2):245-53. DOI: 10.1006/gyno.2000.6042. View

Liu R, Wei H, Gao P, Yu H, Wang K, Fu Z . CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017; 8(24):39021-39032. PMC: 5503592. DOI: 10.18632/oncotarget.16547. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W . Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017; 147(1):181-187. DOI: 10.1016/j.ygyno.2017.07.007. View

Zeng X, Xie H, Yuan J, Jiang X, Yong J, Zeng D . M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 2019; 20(7):956-966. PMC: 6606001. DOI: 10.1080/15384047.2018.1564567. View

Gerner E, Meyskens Jr F . Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004; 4(10):781-92. DOI: 10.1038/nrc1454. View

10.

Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T . Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013; 12(3):259-67. DOI: 10.7785/tcrt.2012.500312. View

11.

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

12.

Rowswell-Turner R, Singh R, Urh A, Yano N, Kim K, Khazan N . HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression. J Immunol. 2021; 206(10):2478-2488. DOI: 10.4049/jimmunol.2000281. View

13.

Wesolowski R, Sharma N, Reebel L, Rodal M, Peck A, West B . Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019; 11:1758835919854238. PMC: 6589951. DOI: 10.1177/1758835919854238. View

14.

Wang J, Li D, Cang H, Guo B . Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019; 8(10):4709-4721. PMC: 6712467. DOI: 10.1002/cam4.2327. View

15.

Kadomoto S, Izumi K, Mizokami A . The CCL20-CCR6 Axis in Cancer Progression. Int J Mol Sci. 2020; 21(15). PMC: 7432448. DOI: 10.3390/ijms21155186. View

16.

Hutchins A, Diez D, Miranda-Saavedra D . The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013; 12(6):489-98. PMC: 3838198. DOI: 10.1093/bfgp/elt028. View

17.

Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J . Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis. Onco Targets Ther. 2019; 12:8687-8699. PMC: 6814357. DOI: 10.2147/OTT.S216355. View

18.

Steitz A, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen J . Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis. 2020; 11(4):249. PMC: 7171168. DOI: 10.1038/s41419-020-2438-8. View

19.

Yunna C, Mengru H, Lei W, Weidong C . Macrophage M1/M2 polarization. Eur J Pharmacol. 2020; 877:173090. DOI: 10.1016/j.ejphar.2020.173090. View

20.

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View